Cargando…

USP32 confers cancer cell resistance to YM155 via promoting ER-associated degradation of solute carrier protein SLC35F2

Background: The most commonly preferred chemotherapeutic agents to treat cancers are small-molecule drugs. However, the differential sensitivity of various cancer cells to small molecules and untargeted delivery narrow the range of potential therapeutic applications. The mechanisms responsible for d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chandrasekaran, Arun Pandian, Kaushal, Kamini, Park, Chang-Hwan, Kim, Kye-Seong, Ramakrishna, Suresh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8581437/ https://www.ncbi.nlm.nih.gov/pubmed/34815782 http://dx.doi.org/10.7150/thno.63806

Ejemplares similares

YM155 sensitizes HeLa cells to TRAIL-mediated apoptosis via cFLIP and survivin downregulation
por: Chandrasekaran, Arun Pandian, et al.
Publicado: (2020)

CRISPR/Cas9-based genome-wide screening for deubiquitinase subfamily identifies USP1 regulating MAST1-driven cisplatin-resistance in cancer cells
por: Tyagi, Apoorvi, et al.
Publicado: (2022)

USP48 Governs Cell Cycle Progression by Regulating the Protein Level of Aurora B
por: Antao, Ainsley Mike, et al.
Publicado: (2021)

E3 Ubiquitin Ligase APC/C(Cdh1) Regulation of Phenylalanine Hydroxylase Stability and Function
por: Tyagi, Apoorvi, et al.
Publicado: (2020)

YM155 Induces EGFR Suppression in Pancreatic Cancer Cells
por: Na, Young-Soon, et al.
Publicado: (2012)

Deubiquitinating enzymes as cancer biomarkers: new therapeutic opportunities?
por: Poondla, Naresh, et al.
Publicado: (2019)

Survivin inhibition with YM155 ameliorates experimental pulmonary arterial hypertension
por: Blanco, Isabel, et al.
Publicado: (2023)

YM155 enhances the cytotoxic activity of etoposide against canine osteosarcoma cells
por: ONG, Siew Mei, et al.
Publicado: (2019)

Epigenetic Changes at the Birc5 Promoter Induced by YM155 in Synovial Sarcoma
por: Mika, Aleksander, et al.
Publicado: (2019)

YM155 Inhibits NleB and SseK Arginine Glycosyltransferase Activity
por: Zhu, Congrui, et al.
Publicado: (2021)

The over-expression of survivin enhances the chemotherapeutic efficacy of YM155 in human hepatocellular carcinoma
por: Xia, Hongping, et al.
Publicado: (2015)

Effects of YM155 on survivin levels and viability in neuroblastoma cells with acquired drug resistance
por: Voges, Yvonne, et al.
Publicado: (2016)

Lapatinib potentiates cytotoxicity of YM155 in neuroblastoma via inhibition of the ABCB1 efflux transporter
por: Radic-Sarikas, Branka, et al.
Publicado: (2017)

Effect of Sepatronium Bromide (YM-155) on DNA Double-Strand Breaks Repair in Cancer Cells
por: Majera, Dusana, et al.
Publicado: (2020)

Targeting abundant survivin expression in liposarcoma: subtype dependent therapy responses to YM155 treatment
por: Vay, Christian, et al.
Publicado: (2021)

Deubiquitinating Enzyme-Mediated Signaling Networks in Cancer Stem Cells
por: Kaushal, Kamini, et al.
Publicado: (2020)

Ubiquitin Specific Protease 29 Functions as an Oncogene Promoting Tumorigenesis in Colorectal Carcinoma
por: Chandrasekaran, Arun Pandian, et al.
Publicado: (2021)

Survivin selective inhibitor YM155 induce apoptosis in SK-NEP-1 Wilms tumor cells
por: Tao, Yan-Fang, et al.
Publicado: (2012)

YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathway
por: Chang, Bill H, et al.
Publicado: (2015)

Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1
por: Wagner, Verena, et al.
Publicado: (2014)

Action of YM155 on clear cell renal cell carcinoma does not depend on survivin expression levels
por: Sim, Mei Yi, et al.
Publicado: (2017)

Dioxonaphthoimidazoliums AB1 and YM155 disrupt phosphorylation of p50 in the NF-κB pathway
por: Ho, Si Han Sherman, et al.
Publicado: (2016)

Testing of the Survivin Suppressant YM155 in a Large Panel of Drug-Resistant Neuroblastoma Cell Lines
por: Michaelis, Martin, et al.
Publicado: (2020)

Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs
por: Iwasa, T, et al.
Publicado: (2010)

Interleukin Enhancer-binding Factor 3/NF110 Is a Target of YM155, a Suppressant of Survivin
por: Nakamura, Naoto, et al.
Publicado: (2012)

Survivin inhibitor YM155 suppresses gastric cancer xenograft growth in mice without affecting normal tissues
por: Cheng, Xiao Jiao, et al.
Publicado: (2016)

YM155 decreases radiation-induced invasion and reverses epithelial–mesenchymal transition by targeting STAT3 in glioblastoma
por: Zhang, Xin, et al.
Publicado: (2018)

Structure-Activity Relationship Analysis of YM155 for Inducing Selective Cell Death of Human Pluripotent Stem Cells
por: Go, Young-Hyun, et al.
Publicado: (2019)

YM155 potently triggers cell death in breast cancer cells through an autophagy-NF-kB network
por: Véquaud, Eloïse, et al.
Publicado: (2015)

Anti-GD2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells
por: Gholizadeh, Shima, et al.
Publicado: (2018)

Correction to: YM155 decreases radiation-induced invasion and reverses epithelial–mesenchymal transition by targeting STAT3 in glioblastoma
por: Zhang, Xin, et al.
Publicado: (2021)

Ym155 localizes to the mitochondria leading to mitochondria dysfunction and activation of AMPK that inhibits BMP signaling in lung cancer cells
por: Mondal, Arindam, et al.
Publicado: (2022)

YM155, specific survivin inhibitor, can enhance artesunate-induced cytotoxicity in HCT116 colon cancer cells
por: Kim, Eui Tae, et al.
Publicado: (2020)

E3 Ubiquitin Ligase APC/C(Cdh1) Negatively Regulates FAH Protein Stability by Promoting Its Polyubiquitination
por: Kaushal, Kamini, et al.
Publicado: (2020)

Antitumor effect of YM155, a novel small-molecule survivin suppressant, via mitochondrial apoptosis in human MFH/UPS
por: MINODA, MASAYA, et al.
Publicado: (2015)

Early Cellular Responses of Prostate Carcinoma Cells to Sepantronium Bromide (YM155) Involve Suppression of mTORC1 by AMPK
por: Danielpour, David, et al.
Publicado: (2019)

Remarkable Synergy When Combining EZH2 Inhibitors with YM155 Is H3K27me3-Independent
por: Yang, Jun, et al.
Publicado: (2022)

TAT-IL-24-KDEL-induced apoptosis is inhibited by survivin but restored by the small molecular survivin inhibitor, YM155, in cancer cells
por: Zhang, Jian, et al.
Publicado: (2016)

YM155-Adapted Cancer Cell Lines Reveal Drug-Induced Heterogeneity and Enable the Identification of Biomarker Candidates for the Acquired Resistance Setting
por: Michaelis, Martin, et al.
Publicado: (2020)

Hypoxia represses early responses of prostate and renal cancer cells to YM155 independent of HIF-1α and HIF-2α
por: Danielpour, David, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vtfsa8qg6sk3p7q8e1ig1onver